Connect with us


Best Stocks To Buy Now? 5 Health Care Stocks In Focus

Could these health care stocks be the remedy to investors’ recent stock market pains?
The post Best Stocks To Buy Now? 5 Health Care Stocks In Focus…



5 Top Health Care Stocks To Add To Your Radar This Week

For investors wondering why are stocks tanking in the stock market now, health care stocks could be worth looking at. On the whole, the ever-vital health care industry has and continues to play crucial roles during the coronavirus pandemic. From the more obvious vaccine-making names to the day-to-day health care providers, this is apparent. Even as the world aims to transition towards endemic living, there is more focus on health care now than ever. As people attempt to stay healthy amidst these trying times, investors could be considering jumping into this defensive sector in the stock market today.

For one thing, some of the top players in the health care scene today continue to draw attention. Namely, the likes of BioNTech (NASDAQ: BNTX) are among the industry players gaining attention this week. To point out, BioNTech’s latest quarterly earnings update seems to be turning heads across the board. In it, the coronavirus vaccine firm saw its revenue soar by 211% year-over-year. This would be thanks to sales from its coronavirus shot jointly developed with Pfizer (NYSE: PFE). All in all, the health care industry continues to power on despite the additional pressure from the endemic. On that note, here are five more to watch today.

Health Care Stocks To Buy [Or Sell] Today

Moderna Inc.

biotech stocks (MRNA stock)

Starting us off today, we have Moderna, a biopharmaceutical company that continues to advance programs in the field of messenger RNA (mRNA). In fact, the company has a pipeline of vaccines in the works after the huge success of its coronavirus vaccine. This would include an influenza and HIV vaccine that could prove to be game-changing as well. Last week, the company reported its first-quarter financials for 2022.

Diving in, it generated $6.1 billion in revenue, compared to $1.9 billion a year earlier. This increase is primarily due to the increase in its coronavirus vaccine sales.Net income for the quarter was $3.7 billion or a diluted earnings per share of $8.58. The company also ended the quarter with $19.3 billion in cash. “Beginning in the fall of 2022, our robust Phase 3 pipeline could lead to three respiratory commercial launches over the next two to three years. We also look forward to advancing our therapeutic programs and sharing proof-of-concept readouts on our rare genetic disease programs for propionic acidemia and methylmalonic acidemia, and on our personalized cancer vaccine program this year,” said Stéphane Bancel, Chief Executive Officer of Moderna. Given the impressive quarter, is MRNA stock worth investing in right now?

[Read More] Stock Market Today: Dow Jones, S&P 500 Tumbles; Palantir Stock Down On Mixed Earnings

Veru Inc.

top biotech stocks (VERU stock)

Veru is a biopharmaceutical company that develops novel medicines for the coronavirus and other viral diseases. It also develops treatments for breast and prostate cancers. Notably, its Sabizabulin drug has dual antiviral and anti-inflammatory effects. It is also being developed as a potential treatment for hospitalized coronavirus patients at high risk for acute respiratory distress syndrome. On May 2, 2022, the company announced that the FDA has granted the company a pre-emergency use authorization meeting on May 10, 2022, for the positive Phase 3 study for Sabizabulin.

Its findings indicate positive efficacy and safety results from a double-blind, randomized placebo-controlled trial. In the trial, it was shown that the drug candidate could reduce deaths by 55% in hospitalized patients. The Independent Data Safety Monitoring Committee unanimously recommended that the Phase 3 study be halted early due to efficacy, and they further remarked that no safety concerns were identified. Given this exciting piece of news, should you consider adding VERU stock to your portfolio?

Biogen Inc.

top health care stocks (BIIB stock)

Biogen is a health care company that develops innovative therapies for people living with serious neurological diseases worldwide. Accordingly, it is one of the world’s first global biotechnology companies and continues to be a leading health care company with its portfolio of treatments. The company is also commercializing biosimilars and is focusing on its neuroscience pipeline.

Last week, the company announced together with MedRhythms that they will develop and commercialize MR-004, an investigational prescription digital therapeutic for the potential treatment of gait deficits in multiple sclerosis (MS). The collaboration combines MedRhythms’ digital expertise with Biogen’s leadership in MS to address significant unmet patient needs. If approved, MR-004 has the potential to become the first prescription digital therapeutic for gait deficit in MS. With that being said, is BIIB stock a buy?

[Read More] Gaming Stocks To Invest In Right Now? 5 Names To Know

Novavax Inc.

best biotech stocks (NVAX stock)

Another health care name to take note of in the stock market today would be Novavax. Overall, the biotech company specializes in the development of vaccines for serious infectious diseases. The like of which range from Ebola, influenza, respiratory syncytial viruses, and COVID-19, to name a few. For investors keen to jump on upcoming names in the coronavirus vaccine space, NVAX stock could be a viable play.

Speaking of its coronavirus shot, Novavax appears to be firing on all cylinders on this front. Just last week, the company made two key regulatory submissions. Firstly, on May 6, Novavax applied to expand the use of its vaccine in Australian and New Zealand teens aged 12 to 17 years. Secondly, the company made a similar application in Britain for adolescents aged 12 and older earlier in the week. With Novavax’s current momentum in mind, will you be keeping an eye on NVAX stock?

[Read More] 4 Top Oil Stocks To Watch In The Stock Market Today

UnitedHealth Group Inc.

best health care stocks to buy now (UNH stock)

Topping off our list today is the UnitedHealth Group or UNH, for short. In brief, UNH is a multinational managed health care and insurance firm. As you can imagine the company primarily offers consumers health care solutions and insurance services. For a sense of scale, UNH serves 148 million individuals via its partnerships with governments, employers, and health care providers. Because of all this, investors looking for more defensive names in the health care space may be considering UNH stock.

On the whole, the company appears to be going strong on the operational front as well. Just last month, UNH beat Wall Street’s estimates at the top and bottom line in its latest quarterly earnings release. Getting straight to it, the company is looking at earnings of $5.49 on revenue of $1.33 billion. For revenue, UNH is boasting commendable year-over-year gains of 14%. This, according to the company, is thanks to double-digit growth across its core Optum and UnitedHealthcare sections. This alongside UNH raising its full-year outlook would suggest that the company is not slowing down anytime soon. As such, would UNH stock be a top pick in your books?

If you enjoyed this article and you’re interested in learning how to trade so you can have the best chance to profit consistently then you need to checkout this YouTube channel. CLICK HERE RIGHT NOW!!

The post Best Stocks To Buy Now? 5 Health Care Stocks In Focus appeared first on Stock Market News, Quotes, Charts and Financial Information |

Read More

Continue Reading


Cruise Line Drops Pre-Cruise Covid Testing Rule

The major cruise lines walk a delicate line. They need to take the actual steps required to keep their passengers safe and they also need to be aware of…



The major cruise lines walk a delicate line. They need to take the actual steps required to keep their passengers safe and they also need to be aware of how things look to the outside public. It's a mix of practical covid policy balanced with covid theater.

You have to do the right thing -- and Royal Caribbean International (RCL) - Get Royal Caribbean Group Report, Carnival Cruise Lines (CCL) - Get Carnival Corporation Report, and Norwegian Cruise Lines (NCLH) - Get Norwegian Cruise Line Holdings Ltd. Report have been doing that with very meticulous protocols-- but you also have to show the general public you're taking the pandemic seriously. The cruise industry has been under the microscope of both public perception and the Centers for Disease Control (CDC) since covid first appeared.

That's not because you're likely to get infected on a cruise ship than at a concert, sporting event, theme park, restaurant, or any other crowded space. It's because when you get sick at one of those locations nobody can pinpoint the source of your infection

Cruises last from 3 days to 7 days or even longer and that means that some people will get covid onboard and that will be blamed on the cruise industry. To mitigate that Carnival, Royal Caribbean, and Norwegian have rigid protocols in place that require passengers 12 and over to be vaccinated as well as pre-cruise covid tests taken no more than two days before your cruise leaves.

Once cruise line has dropped that testing requirement (at least on a few sailings) and that could lead Royal Caribbean, Carnival, and Norwegian to follow. 

Sina Schuldt/picture alliance via Getty

Holland America Drops Some Covid Testing

As the largest cruise lines sailing from the U.S., Royal Caribbean, Carnival, and Norwegian don't want to be the first to make major covid policy changes. They acted more or less in tandem when it came to loosening, then dropping mask rules and have generally followed the lead of the CDC, even when that agency's rules became optional.

Now, Holland America cruise line has dropped pre-cruise covid testing on a handful of cruises. It's a minor move, but it does provide cover and precedent for Royal Caribbean, Carnival, and Norwegian to eventually do the same.

"Holland America Line becomes the first US-based cruise line to remove testing for select cruises. Unfortunately for those taking a cruise from the United States, the new protocols are only in place for certain cruises onboard the company’s latest ship, the Rotterdam, in Europe," Cruisehive reported.

The current CDC guidelines do recommend pre-cruise testing, but the cruise lines into following those rules. By picking cruises sailing out of Europe, Holland America avoids picking a fight with the federal agency just yet, but it will be able to gather data as to whether the pre-cruise testing actually helps.

Holland America has not changed its vaccination requirements for those cruises which mirror the 12-and-up rule used by Royal Caribbean, Carnival, and Norwegian.

Some guests have called for the end of the testing requirement because they believe it's more theater than precaution because people can test and then contract covid while traveling to their cruise.

The Current Cruise Protocols Work

Royal Caribbean President Michael Bayley does expect changes to come in his cruise line's covid protocols, and he talked about them during Royal Caribbean's recent President's Cruise, the Royal Caribbean Blog reported.

"I think pre cruise testing is going to be around for another couple of months," Bayley told passengers during a question and answer session. "We obviously want it to go back to normal, but we're incredibly cognizant of our responsibilities to keep our crew, the communities and our guests safe."

People do still get covid onboard despite the crew being 100% vaccinated and all passengers 12 and over being vaccinated, but the protocols have worked well when it comes to preventing serious illness.

Bayley said that the CDC shared some information with him in a call.

"The cruise industry sailing out of the US ports over the past 12 months and how many people have been hospitalized with Covid and how many deaths occurred from Covid from people who'd sailed on the industry's ships, which is in the millions," he said, "And the number of people who died from COVID who'd sailed on ships over the past year was two."

That success may be why the major cruise lines are reluctant to make changes. The current rules, even if they're partially for show, have been incredibly effective.

"Two is terrible. But but but against the context of everything we've seen, that's it's truly been a remarkable success." he added.

Read More

Continue Reading


Tesla Rivals Challenge Its Lead as Nio Sets Encouraging Record

Tesla’s rivals are not even coming close to producing and delivering EVs at the same rate as the Austin, Texas-based market leader.



Tesla's rivals are not even coming close to producing and delivering EVs at the same rate as the Austin, Texas-based market leader.

Electric vehicle makers have been struggling over the last two years to produce and deliver cars, trucks and SUVs despite obstacles such as supply chain disruptions, semiconductor shortages and factory shutdowns caused by the covid pandemic.

The industry's leading EV manufacturer Tesla  (TSLA) - Get Tesla Inc. Report on July 2 said that plant closures at its Shanghai gigafactory in April and May and supply chain disruptions led to a smaller number of deliveries than expected in its second quarter ending June 30 with 254,695, which was 26.7% higher than the same period in 2021, but 17.7% lower than its record of 310,048 delivered in the first quarter of 2021. Analysts were originally expecting about 295,000 deliveries.

Tesla's production declined to 258,580 vehicles in the second quarter compared to 305,407 in the first quarter. It had produced 305,840 vehicles in the fourth quarter of 2021.

Tesla's rivals are not even coming close to producing and delivering EVs at the same rate as the Austin, Texas-based market leader. But they keep trying.


Tesla Rivals Struggle to Produce and Deliver Volume of EVs

Tesla rival Nio  (NIO) - Get NIO Inc. American depositary shares each representing one Class A 蔚来汽车 Report on July 1 said that it had delivered 12,961 vehicles in June for a 60.3% year-over-year increase and its highest number of monthly deliveries ever. The company also reported 25,059 EVs delivered in the three months ending June 2022, increasing by 14.4% year-over-year. Nio has delivered a cumulative 217,897 EVs as of June 30.

NIO on June 15 rolled out its ES7, a new mid-large five-seat smart electric SUV, which is the first SUV product based on NIO's latest technology platform Technology 2.0. NIO also launched the 2022 ES8, ES6 and EC6 equipped with the upgraded digital cockpit domain controller and sensing suite, enhancing the computing and perception capabilities as well as digital experience of the vehicles. The company expects to start deliveries of the ES7 and the ES8, ES6 and EC6 in August.

Chinese EV maker XPeng  (XPEV) - Get XPeng Inc. American depositary shares each representing two Class A 小鹏汽车 Report on July 1 said it delivered 15,295 vehicles in June, a 133% increase year-over-year; 34,422 in the second quarter ending June 30 for a 98% increase year-over-year and 68,983 in the first six months of the year for a 124% increase year-over year.

The Guangzhou, China-based company said in August it will begin accepting orders for its new G9 SUV with an official launch in September.

Beijing-based Li Auto  (LI) - Get Li Auto Inc. Report on July 1 said it delivered 13,024 EVs in June, a 68.9% increase year-over-year and 28,687 in the second quarter ending June 30 for a 63.2% increase year-over-year. The company on June 21 began taking orders for its Li L9 SUV and recorded 30,000 orders as of June 24, according to a statement. Test drives will begin July 16 with deliveries beginning by the end of August.

GM Follows Behind Tesla and Other Rivals

General Motors  (GM) - Get General Motors Company Report had 7,300 EV sales in the second quarter, according to a July 1 statement. The Detroit automaker's sales included deliveries of the BrightDrop Zevo 600 delivery van, GMC Hummer EV pickup, and the resumption of the Chevrolet Bolt EV and Bolt EUV production.

GM said the Cadillac Lyriq production is accelerating, with initial deliveries in process. Orders for the 2023 model year sold out within hours and preorders for the 2024 model opened on June 22.

The company said it will gradually increase production of the Cadillac Lyriq and GMC Hummer EV Pickup in the second half of 2022. 

Read More

Continue Reading

Spread & Containment

Tesla EV deliveries fall nearly 18% in second quarter following China factory shutdown

Tesla delivered 254,695 electric vehicles globally in the second quarter, a nearly 18% drop from the previous period as supply chain constraints, China’s…



Tesla delivered 254,695 electric vehicles globally in the second quarter, a nearly 18% drop from the previous period as supply chain constraints, China’s extended COVID-19 lockdown and challenges around opening factories in Berlin and Austin took their toll on the company.

This is the first time in two years that Tesla deliveries, which were 310,048 in the first period this year, have fallen quarter over quarter. Tesla deliveries were up 26.5% from the second quarter last year.

The quarter-over-quarter reduction is in line with a broader supply chain problem in the industry. It also illustrates the importance of Tesla’s Shanghai factory to its business. Tesla shuttered its Shanghai factory multiple times in March due to rising COVID-19 cases that prompted a government shutdown.

Image Credits: Tesla/screenshot

The company said Saturday it produced 258,580 EVs, a 15% reduction from the previous quarter when it made 305,407 vehicles.

Like in other quarters over the past two years, most of the produced and delivered vehicles were Model 3 and Model Ys. Only 16,411 of the produced vehicles were the older Model S and Model X vehicles.

Tesla said in its released that June 2022 was the highest vehicle production month in Tesla’s history. Despite that milestone, the EV maker as well as other companies in the industry, have struggled to keep apace with demand as supply chain problems persist.

Read More

Continue Reading